

Successful Administration of Ipilimumab to Two Kidney Metastatic Melanoma

Journal of Clinical Oncology

32, e69-e71

DOI: [10.1200/jco.2013.49.2314](https://doi.org/10.1200/jco.2013.49.2314)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
2	Treatment options for metastatic melanoma in solid organ transplant recipients. JAAD Case Reports, 2015, 1, S26-S28.	0.4	1
3	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
4	Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. Melanoma Management, 2015, 2, 311-314.	0.1	22
5	Structure and Potential Cellular Targets of HAMLET-like Anti-Cancer Compounds made from Milk Components. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 773.	0.9	21
6	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Medicine, 2015, 13, 211.	2.3	570
7	Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cellular and Molecular Life Sciences, 2015, 72, 645-658.	2.4	139
8	Merkel Cell Carcinoma and Immunosuppression: What We Still Need to Know. Journal of the National Cancer Institute, 2015, 107, dju422-dju422.	3.0	15
9	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391.	0.6	1,136
10	Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. Immunotherapy, 2016, 8, 677-679.	1.0	7
11	Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation, 2016, 100, 2288-2300.	0.5	99
12	Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. Transplantation Proceedings, 2016, 48, 3137-3141.	0.3	49
13	The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. Advances in Chronic Kidney Disease, 2016, 23, 312-316.	0.6	35
14	The Cancer Conundrum. American Journal of Transplantation, 2016, 16, 1041-1042.	2.6	1
15	Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. Annals of Oncology, 2016, 27, 2304-2305.	0.6	19
16	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. European Journal of Cancer, 2016, 67, 66-72.	1.3	90
17	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research, 2016, 22, 4550-4555.	3.2	73
18	Ipilimumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 811-826.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016, 30, 571-584.	2.2	93
20	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		60
21	Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. , 2016, 4, 64.		75
22	Daunting but Worthy Goal. <i>Transplantation</i> , 2016, 100, 2569-2583.	0.5	16
23	Current status of alloimmunity. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 556-562.	1.0	3
24	Management of High-Risk Squamous Cell Carcinoma of the Skin. <i>Current Treatment Options in Oncology</i> , 2016, 17, 34.	1.3	46
25	Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.	3.4	706
26	Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. <i>New England Journal of Medicine</i> , 2016, 374, 896-898.	13.9	244
27	Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1135-1137.	0.6	131
28	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
29	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	2.0	266
30	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , 2017, 45, 160-169.	1.4	10,656
31	Keratinocyte Cancer Therapies Enter the Era of Targeted and Immunotherapy. <i>JAMA Dermatology</i> , 2017, 153, 253.	2.0	0
32	Skin Cancers in Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 2509-2530.	2.6	151
33	Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature. <i>Journal of Immunotherapy</i> , 2017, 40, 341-344.	1.2	29
34	The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. <i>Melanoma Research</i> , 2017, 27, 519-523.	0.6	16
35	Challenges faced when identifying patients for combination immunotherapy. <i>Future Oncology</i> , 2017, 13, 1607-1618.	1.1	10
36	Immune Checkpoint Inhibitors in Organ Transplant Patients. <i>Journal of Immunotherapy</i> , 2017, 40, 277-281.	1.2	120

#	ARTICLE	IF	CITATIONS
37	A review of serious adverse effects under treatment with checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 136-144.	1.1	56
38	Kidney Toxicities Associated With Novel Cancer Therapies. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 233-240.	0.6	14
39	Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 86-92.	2.0	87
40	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. <i>European Journal of Cancer</i> , 2017, 81, 138-141.	1.3	1
41	Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 73.	0.4	47
42	Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.		20
43	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55
44	Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. <i>Head and Neck</i> , 2017, 39, 578-594.	0.9	86
45	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <i>Oncologist</i> , 2017, 22, 70-80.	1.9	58
46	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. <i>Melanoma Management</i> , 2017, 4, 151-155.	0.1	2
47	Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant. <i>Journal of Onco-Nephrology</i> , 2017, 1, 42-48.	0.3	21
48	Skin Diseases in the Immunosuppressed. , 2018, , .		2
49	Cutaneous Malignancies in Solid Organ Transplant Recipients. , 2018, , 91-116.		0
50	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
51	Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. <i>Cancer Treatment Reviews</i> , 2018, 63, 116-121.	3.4	37
52	Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. <i>Melanoma Research</i> , 2018, 28, 61-64.	0.6	55
53	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1054-1062.	0.6	110
54	Outcomes of patients with a pretransplant history of early-stage melanoma. <i>Melanoma Research</i> , 2018, 28, 471-474.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations. <i>Melanoma Management</i> , 2018, 5, MMT10.	0.1	19
56	Immune checkpoint inhibitors in the management of malignancies in transplant recipients. <i>Postgraduate Medical Journal</i> , 2018, 94, 704-708.	0.9	10
57	Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research. <i>Transplantation Direct</i> , 2018, 4, e376.	0.8	98
58	12 High-Risk Cutaneous Malignancies. , 2018, , .		0
59	Cancer in kidney transplant recipients. <i>Nature Reviews Nephrology</i> , 2018, 14, 508-520.	4.1	137
60	Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. <i>Acta Oncologica</i> , 2018, 57, 1414-1418.	0.8	19
61	Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 981-989.	1.1	11
62	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 3065-3071.	2.6	41
63	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Metastatic Cancer Post Solid Organ Transplantation: A Case Report and Review of the Literature. <i>Transplantation Proceedings</i> , 2019, 51, 3053-3058.	0.3	9
64	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
65	Cancer immunotherapy and its renal effects. <i>Journal of Onco-Nephrology</i> , 2019, 3, 151-159.	0.3	3
66	Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2194.	1.8	28
67	Report on the 2018 Cancer, Autoimmunity, and Immunology Conference. <i>Journal of Immunology</i> , 2019, 202, 2823-2828.	0.4	3
68	Immunotherapy in organ-transplanted cancer patients: efficacy and risk of organ rejection. <i>Annals of Oncology</i> , 2019, 30, 1173-1177.	0.6	11
69	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. <i>Current Opinion in Oncology</i> , 2019, 31, 54-64.	1.1	66
70	Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 82-88.	0.6	39
71	Toxicities associated with checkpoint inhibitors—an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.	0.9	80
72	Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. <i>Oncologist</i> , 2019, 24, 394-401.	1.9	48

#	ARTICLE	IF	CITATIONS
73	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
74	Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. Journal of the American Academy of Dermatology, 2020, 82, 1490-1500.	0.6	108
75	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. Kidney International, 2020, 97, 62-74.	2.6	121
76	Liver transplantation for hepatocellular carcinoma: Management after the transplant. American Journal of Transplantation, 2020, 20, 333-347.	2.6	88
77	Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients. Kidney International Reports, 2020, 5, 149-158.	0.4	52
78	Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation, 2020, 104, 1041-1047.	0.5	30
79	Immuno-oncology for Hepatocellular Carcinoma. Clinics in Liver Disease, 2020, 24, 739-753.	1.0	8
81	Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. Journal of Onco-Nephrology, 2020, 4, 165-170.	0.3	0
82	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. JDDG - Journal of the German Society of Dermatology, 2020, 18, 582-609.	0.4	24
83	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports, 2020, 5, 1139-1148.	0.4	71
84	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.	0.9	62
85	Cutaneous squamous cell carcinoma in the organ transplant recipient. Oral Oncology, 2020, 103, 104562.	0.8	19
86	Cutaneous squamous cell carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 106-110.	0.3	3
87	Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. Journal of Immunotherapy, 2020, 43, 149-152.	1.2	5
89	Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts. American Journal of Transplantation, 2021, 21, 60-72.	2.6	4
90	Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. International Journal of Surgery Oncology, 2021, 2, 49.	0.2	4
91	Melanoma en pacientes receptores de un trasplante de Órgano sólido. Actas Dermo-sifiligráficas, 2021, 112, 216-224.	0.2	3
92	Management of Skin Cancers in Solid Organ Transplant Recipients. , 2021, , 267-286.		0

#	ARTICLE	IF	CITATIONS
93	Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. <i>BMJ Case Reports</i> , 2021, 14, e238037.	0.2	9
94	Melanoma in Solid Organ Transplant Recipients. <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 216-224.	0.2	2
95	Cutaneous Head and Neck Cancers in the High-Risk Immunosuppressed Population. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 397-413.	0.5	0
96	Skin Cancers and Lung Transplant. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 483-496.	0.8	1
97	Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2021, 13, 801-814.	2.2	7
98	High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Clinical Review. <i>Annals of Surgical Oncology</i> , 2021, 28, 9009-9030.	0.7	7
99	T-cell Exhaustion in Organ Transplantation. <i>Transplantation</i> , 2022, 106, 489-499.	0.5	14
100	Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference. <i>Transplantation Reviews</i> , 2021, 35, 100636.	1.2	4
101	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. <i>Kidney International</i> , 2021, 100, 196-205.	2.6	95
102	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	1.7	15
103	Malignancy Following Lung Transplantation. , 2022, , 764-777.		0
104	Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. <i>JAAD Case Reports</i> , 2017, 3, 412-415.	0.4	40
105	Management of checkpoint inhibitor-associated renal toxicities. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 215-223.	0.6	6
106	Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge. <i>Transplantation</i> , 2021, 105, 67-78.	0.5	21
107	Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 72-75.	1.6	11
108	The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. <i>Oncologist</i> , 2020, 25, 505-514.	1.9	93
109	PLK1 Inhibition alleviates transplant-associated obliterative bronchiolitis by suppressing myofibroblast differentiation. <i>Aging</i> , 2020, 12, 11636-11652.	1.4	8
110	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	2.3	393

#	ARTICLE	IF	CITATIONS
111	High-risk Cutaneous Squamous Cell Carcinoma. International Journal of Head and Neck Surgery, 2017, 8, 37-44.	0.1	1
112	Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review. Current Cancer Drug Targets, 2020, 20, 720-727.	0.8	12
113	Renal Toxicity. Advances in Experimental Medicine and Biology, 2020, 1244, 287-293.	0.8	0
114	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.	1.0	6
115	Renal Toxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 389-397.	0.8	0
116	Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.	1.4	0
118	Emerging Concepts in Managing Malignancy in Kidney Transplant Patients. Seminars in Nephrology, 2022, 42, 63-75.	0.6	4
119	Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. Clinical Journal of Gastroenterology, 2022, 15, 755-764.	0.4	3
120	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Korean Journal of Transplantation, 2022, 36, 82-98.	0.0	9
121	Transplant Onconephrology in Patients With Kidney Transplants. Advances in Chronic Kidney Disease, 2022, 29, 188-200.e1.	0.6	4
122	Nephrology (Kidney). , 2022, , 197-214.		0
123	Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma. World Journal of Gastroenterology, 2022, 28, 4929-4942.	1.4	5
124	Immune checkpoint blockade for organ-transplant recipients with cancer: A review. European Journal of Cancer, 2022, 175, 326-335.	1.3	8
126	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Frontiers in Medicine, 0, 9, .	1.2	1
128	Allograft rejection following immune checkpoint inhibitors in solid organ transplant recipients: A safety analysis from a literature review and a pharmacovigilance system. Cancer Medicine, 2023, 12, 5181-5194.	1.3	3
129	Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion. World Journal of Gastrointestinal Surgery, 0, 15, 19-31.	0.8	4
130	Immune checkpoint inhibitors in kidney transplantation. Current Opinion in Organ Transplantation, 2023, 28, 46-54.	0.8	4
131	A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors. Pharmacogenomics and Personalized Medicine, 0, Volume 16, 29-36.	0.4	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------